Literature DB >> 18509107

Functional properties of the carboxy-terminal host cell-binding domains of the two toxins, TcdA and TcdB, expressed by Clostridium difficile.

Tanis Dingle1, Stefanie Wee, George L Mulvey, Antonio Greco, Elena N Kitova, Jiangxiao Sun, Shuangjun Lin, John S Klassen, Monica M Palcic, Kenneth K S Ng, Glen D Armstrong.   

Abstract

The biological and ligand-binding properties of recombinant C-terminal cell-binding domains (CBDs) and subdomains of the two large exotoxins, Toxin A (TcdA) and Toxin B (TcdB) expressed by Clostridium difficile were examined in the hemagglutination and Verocytotoxicity neutralization assays and by qualitative affinity chromatography using Sepharose-linked alpha Gal(1,3)betaGal(1,4)beta Glc as well as the direct electrospray ionization mass spectrometry (ES-MS) assay. These studies revealed that, whereas the full-length TcdA CBD agglutinated rabbit erythrocytes, neutralized TcdA-mediated Vero cell death and bound to alpha Gal(1,3)betaGal(1,4)beta Glc-derivatized Sepharose, the TcdB CBD was inactive in these functional assays. Moreover, retention by alpha Gal(1,3)betaGal(1,4)beta Glc-derivatized Sepharose corresponded to the number of available TcdA subdomain ligand-binding sites. By contrast, the ES-MS assays revealed that both the TcdA and TcdB CBD bind to 8-methoxycarbonyloctyl-alpha Gal(1,3)betaGal(1,4)beta Glc sequences with similar avidities. Additional ES-MS experiments using chemically altered alpha Gal(1,3)betaGal(1,4)beta Glc sequences also revealed that the TcdA and TcdB CBD will tolerate a fair amount of structural variation in their complementary glycan ligands. Although the studies are consistent with the known ligand-binding properties of the TcdA and TcdB holotoxins, they also revealed subtle heretofore unrecognized functional differences in their receptor recognition properties.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18509107     DOI: 10.1093/glycob/cwn048

Source DB:  PubMed          Journal:  Glycobiology        ISSN: 0959-6658            Impact factor:   4.313


  32 in total

1.  Structural determinants of Clostridium difficile toxin A glucosyltransferase activity.

Authors:  Rory N Pruitt; Nicole M Chumbler; Stacey A Rutherford; Melissa A Farrow; David B Friedman; Ben Spiller; D Borden Lacy
Journal:  J Biol Chem       Date:  2012-01-20       Impact factor: 5.157

2.  Structural organization of the functional domains of Clostridium difficile toxins A and B.

Authors:  Rory N Pruitt; Melissa G Chambers; Kenneth K-S Ng; Melanie D Ohi; D Borden Lacy
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-12       Impact factor: 11.205

Review 3.  Bioengineered bugs expressing oligosaccharide receptor mimics: toxin-binding probiotics for treatment and prevention of enteric infections.

Authors:  Adrienne W Paton; Renato Morona; James C Paton
Journal:  Bioeng Bugs       Date:  2009-11-17

4.  Nonantimicrobial drug targets for Clostridium difficile infections.

Authors:  Charles Darkoh; Magdalena Deaton; Herbert L DuPont
Journal:  Future Microbiol       Date:  2017-07-31       Impact factor: 3.165

5.  Identification of an epithelial cell receptor responsible for Clostridium difficile TcdB-induced cytotoxicity.

Authors:  Michelle E LaFrance; Melissa A Farrow; Ramyavardhanee Chandrasekaran; Jinsong Sheng; Donald H Rubin; D Borden Lacy
Journal:  Proc Natl Acad Sci U S A       Date:  2015-05-18       Impact factor: 11.205

6.  Preparation and analysis of glycan microarrays.

Authors:  Jamie Heimburg-Molinaro; Xuezheng Song; David F Smith; Richard D Cummings
Journal:  Curr Protoc Protein Sci       Date:  2011-04

Review 7.  Clostridium difficile colitis: pathogenesis and host defence.

Authors:  Michael C Abt; Peter T McKenney; Eric G Pamer
Journal:  Nat Rev Microbiol       Date:  2016-08-30       Impact factor: 60.633

8.  Variations in TcdB activity and the hypervirulence of emerging strains of Clostridium difficile.

Authors:  Jordi M Lanis; Soumitra Barua; Jimmy D Ballard
Journal:  PLoS Pathog       Date:  2010-08-19       Impact factor: 6.823

Review 9.  Variations in virulence and molecular biology among emerging strains of Clostridium difficile.

Authors:  Jonathan J Hunt; Jimmy D Ballard
Journal:  Microbiol Mol Biol Rev       Date:  2013-12       Impact factor: 11.056

10.  Recombinant Mucin-Type Fusion Proteins with a Galα1,3Gal Substitution as Clostridium difficile Toxin A Inhibitors.

Authors:  Reeja Maria Cherian; Chunsheng Jin; Jining Liu; Niclas G Karlsson; Jan Holgersson
Journal:  Infect Immun       Date:  2016-09-19       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.